Michael Aboud

2.8k total citations · 1 hit paper
31 papers, 1.1k citations indexed

About

Michael Aboud is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Michael Aboud has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 21 papers in Virology and 11 papers in Emergency Medicine. Recurrent topics in Michael Aboud's work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (13 papers). Michael Aboud is often cited by papers focused on HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (13 papers). Michael Aboud collaborates with scholars based in United Kingdom, United States and Spain. Michael Aboud's co-authors include Brian Wynne, Martin Gartland, Mark Underwood, Kimberly Y. Smith, Kati Vandermeulen, Lesley Kahl, Cynthia Brinson, Elizabeth A. Blair, Ranjababu Kulasegaram and Ali Elgalib and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Michael Aboud

30 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Aboud United Kingdom	13	950	703	407	172	55	31	1.1k
Cheryl McDonald United States	14	619 0.7×	431 0.6×	212 0.5×	154 0.9×	102 1.9×	27	769
Hal Martin United States	21	1.6k 1.7×	1.2k 1.6×	838 2.1×	252 1.5×	135 2.5×	44	1.8k
Martin Gartland United Kingdom	11	794 0.8×	634 0.9×	262 0.6×	117 0.7×	42 0.8×	19	866
Steven G. Deeks United States	2	403 0.4×	331 0.5×	356 0.9×	185 1.1×	14 0.3×	2	636
Nomathemba Chandiwana South Africa	9	474 0.5×	248 0.4×	372 0.9×	105 0.6×	27 0.5×	26	628
Heather A. Algren United States	6	776 0.8×	657 0.9×	925 2.3×	100 0.6×	12 0.2×	7	1.1k
Barbara A. da Silva United States	10	500 0.5×	427 0.6×	455 1.1×	103 0.6×	11 0.2×	11	794
Christiane Moecklinghoff Germany	14	592 0.6×	492 0.7×	258 0.6×	103 0.6×	25 0.5×	34	728
Donnie McGrath United States	14	970 1.0×	683 1.0×	372 0.9×	154 0.9×	43 0.8×	19	1.1k
Lisa Hamzah United Kingdom	13	430 0.5×	139 0.2×	289 0.7×	142 0.8×	25 0.5×	42	531

Countries citing papers authored by Michael Aboud

Since Specialization

Citations

This map shows the geographic impact of Michael Aboud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Aboud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Aboud more than expected).

Fields of papers citing papers by Michael Aboud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Aboud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Aboud. The network helps show where Michael Aboud may publish in the future.

Co-authorship network of co-authors of Michael Aboud

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Aboud. A scholar is included among the top collaborators of Michael Aboud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Aboud. Michael Aboud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pierone, Gerald, Jennifer S Fusco, Vani Vannappagari, et al.. (2022). Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting. Antiviral Therapy. 27(1). 2 indexed citations

Wyk, Jean van, F. Ajana, Fiona Bisshop, et al.. (2021). Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study). HIV Medicine. 22. 28–28.

Osiyemi, Olayemi, Faïza Ajana, Fiona Bisshop, et al.. (2021). 900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study). Open Forum Infectious Diseases. 8(Supplement_1). S541–S541. 7 indexed citations

Wohlfeiler, Michael, Karam Mounzer, Laurence Brunet, et al.. (2020). Antiretroviral therapy and liver disorders in the OPERA^® cohort. Therapeutic Advances in Drug Safety. 11. 585518905–585518905. 1 indexed citations

Fusco, Jennifer S, Cassidy Henegar, E. Byrd Quinlivan, et al.. (2019). Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Current HIV Research. 17(4). 266–276. 1 indexed citations

Pierone, Gerald, Cassidy Henegar, Jennifer S Fusco, et al.. (2019). Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA^® Observational Database. Journal of the International AIDS Society. 22(12). e25418–e25418. 4 indexed citations

Aboud, Michael, Chloe Orkin, Daniel Podzamczer, et al.. (2019). Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet HIV. 6(9). e576–e587. 77 indexed citations

Aboud, Michael, Richard Kaplan, Johannes Lombaard, et al.. (2019). Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. The Lancet Infectious Diseases. 19(3). 253–264. 104 indexed citations

Janulis, Patrick, Roy M. Gulick, Carole L. Wallis, et al.. (2019). Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. Journal of Antimicrobial Chemotherapy. 74(8). 2365–2369. 7 indexed citations

10.

Aboud, Michael, Richard Kaplan, Johannes Lombaard, et al.. (2019). Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Journal of Infection and Public Health. 12(1). 107–107. 5 indexed citations

11.

Hsu, Ricky, Jennifer S Fusco, Cassidy Henegar, et al.. (2018). Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety. 9(12). 675–686. 7 indexed citations

12.

Llibre, Josep M., Chien‐Ching Hung, Cynthia Brinson, et al.. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet. 391(10123). 839–849. 243 indexed citations breakdown →

13.

Vannappagari, Vani, Leigh Ragone, Cassidy Henegar, et al.. (2018). Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review. Antiviral Therapy. 24(6). 393–404. 13 indexed citations

14.

McComsey, Grace A., Sergio Lupo, Lesley Kahl, et al.. (2017). Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 32(4). 477–485. 43 indexed citations

15.

Walmsley, Sharon, Gary Richmond, Fritz Bredeek, et al.. (2017). Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender. Open Forum Infectious Diseases. 4(suppl_1). S427–S427. 1 indexed citations

16.

Hagins, Debbie, Craig Dietz, Mamta K. Jain, et al.. (2016). Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups. Open Forum Infectious Diseases. 3(suppl_1). 10 indexed citations

17.

Trottier, Benoît, Jordan E. Lake, Cynthia Brinson, et al.. (2016). Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Antiviral Therapy. 22(4). 295–305. 82 indexed citations

18.

Aboud, Michael, Ali Elgalib, Laura W. Pomeroy, et al.. (2010). Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. International Journal of Clinical Practice. 64(9). 1252–1259. 45 indexed citations

19.

Elgalib, Ali, Michael Aboud, Jane Mullen, et al.. (2010). Clinical Utility of Genotypic Resistance Tests for HIV-1-Infected Patients with Low-Level Virological Failure. Journal of Clinical Microbiology. 48(9). 3358–3359. 3 indexed citations

20.

Aboud, Michael, Ali Elgalib, Ranjababu Kulasegaram, & B Peters. (2007). Insulin resistance and HIV infection: a review. International Journal of Clinical Practice. 61(3). 463–472. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact